A Dark Vector Cognition product

Item 1. Financial Statements

56K characters. Original on sec.gov ·

Item 1. Financial Statements

The 20 tables in Item 1. Financial Statements as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

LAM RESEARCH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

Three Months Ended
September 27, 2026September 28, 2025
Revenue$8,219,418$5,324,173
Cost of goods sold3,920,5652,639,294
Gross margin4,298,8532,684,879
Research and development666,398576,446
Selling, general, and administrative348,728279,345
Total operating expenses1,015,126855,791
Operating income3,283,7271,829,088
Other income (expense), net28,49330,074
Income before income taxes3,312,2201,859,162
Income tax expense(559,082)(290,502)
Net income$2,753,138$1,568,660
Net income per share:
Basic$2.20$1.24
Diluted$2.19$1.24
Number of shares used in per share calculations:
Basic1,250,8831,264,446
Diluted1,255,7681,269,313

See Notes to Condensed Consolidated Financial Statements

Lam Research Corporation 2027 Q1 10-Q 4

LAM RESEARCH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)

(unaudited)

Three Months Ended
September 27, 2026September 28, 2025
Net income$2,753,138$1,568,660
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment9,829(12,726)
Cash flow hedges:
Net unrealized (losses) gains during the period(3,695)8,570
Net gains reclassified into net income(6,421)(7,095)
(10,116)1,475
Defined benefit plans, net change in unrealized component9083
Other comprehensive income (loss), net of tax(197)(11,168)
Comprehensive income$2,752,941$1,557,492

See Notes to Condensed Consolidated Financial Statements

Lam Research Corporation 2027 Q1 10-Q 5

LAM RESEARCH CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except per share data)

September 27, 2026June 28, 2026
(unaudited)(1)
ASSETS
Cash and cash equivalents$7,437,384$5,579,171
Accounts receivable, less allowance of $8,358 as of September 27, 2026, and $8,071 as of June 28, 20265,658,3795,339,682
Inventories4,550,5444,276,111
Prepaid expenses and other current assets477,805415,741
Total current assets18,124,11215,610,705
Property and equipment, net3,126,0292,956,472
Goodwill and intangible assets, net1,911,5471,895,859
Other assets3,191,3683,066,707
Total assets$26,353,056$23,529,743
LIABILITIES AND STOCKHOLDERS’ EQUITY
Trade accounts payable$1,592,208$1,302,467
Accrued expenses and other current liabilities3,287,4632,351,541
Deferred profit2,429,3422,279,168
Current portion of long-term debt and finance lease obligations3,4864,073
Total current liabilities7,312,4995,937,249
Long-term debt and finance lease obligations3,731,9583,730,490
Income taxes payable684,273681,197
Other long-term liabilities715,852709,886
Total liabilities12,444,58211,058,822
Commitments and contingencies (refer to Note 12)
Stockholders’ equity:
Preferred stock, at par value of $0.001 per share; authorized, 5,000 shares, none outstanding——
Common stock, at par value of $0.001 per share; authorized, 4,000,000 shares as of September 27, 2026 and June 28, 2026; issued and outstanding, 1,249,145 shares as of September 27, 2026, and 1,251,278 shares as of June 28, 20261,2491,251
Additional paid-in capital9,363,4089,244,449
Treasury stock, at cost; 1,712,490 shares as of September 27, 2026, and 1,710,109 shares as of June 28, 2026(32,620,072)(31,597,945)
Accumulated other comprehensive loss(127,285)(127,088)
Retained earnings37,291,17434,950,254
Total stockholders’ equity13,908,47412,470,921
Total liabilities and stockholders’ equity$26,353,056$23,529,743

(1)Derived from audited financial statements

See Notes to Condensed Consolidated Financial Statements

Lam Research Corporation 2027 Q1 10-Q 6

LAM RESEARCH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

Three Months Ended
September 27, 2026September 28, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income$2,753,138$1,568,660
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization122,072101,644
Deferred income taxes(55,300)(62,875)
Equity-based compensation expense114,69697,241
Other, net27,633(1,890)
Changes in operating assets and liabilities535,41376,184
Net cash provided by operating activities3,497,6521,778,964
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures and intangible assets(257,697)(185,121)
Other, net(9,292)(927)
Net cash used for investing activities(266,989)(186,048)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on debt, including finance lease obligations and payments for debt issuance costs(34,489)(1,417)
Treasury stock purchases, including excise tax payments(1,024,965)(975,791)
Dividends paid(325,402)(291,981)
Proceeds from issuance of common stock, net of issuance costs4,263—
Other, net(1,786)(12,449)
Net cash used for financing activities(1,382,379)(1,281,638)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash4,663(7,059)
Net change in cash, cash equivalents, and restricted cash1,852,947304,219
Cash, cash equivalents, and restricted cash at beginning of period (1)5,597,9436,407,656
Cash, cash equivalents, and restricted cash at end of period (1)$7,450,890$6,711,875
Schedule of non-cash transactions:
Accrued payables for stock repurchases, including applicable excise tax$31,512$58,827
Accrued payables for capital expenditures141,96595,745
Dividends payable412,218327,507
Transfers of finished goods inventory to property and equipment37,05322,897
Reconciliation of cash, cash equivalents, and restricted cashSeptember 27, 2026September 28, 2025
Cash and cash equivalents$7,437,384$6,693,046
Restricted cash and cash equivalents (1)13,50618,829
Total cash, cash equivalents, and restricted cash$7,450,890$6,711,875

(1)Restricted cash is reported within Other assets in the Condensed Consolidated Balance Sheets

See Notes to Condensed Consolidated Financial Statements

Lam Research Corporation 2027 Q1 10-Q 7

LAM RESEARCH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands)

(unaudited)

Three Months Ended
September 27, 2026
Common Stock SharesCommon StockAdditional Paid-in CapitalTreasury StockAccumulated Other Comprehensive LossRetained EarningsTotal
Balance at June 28, 20261,251,278$1,251$9,244,449$(31,597,945)$(127,088)$34,950,254$12,470,921
Issuance of common stock248—4,263———4,263
Purchase of treasury stock(2,381)(2)—(1,022,127)——(1,022,129)
Equity-based compensation expense——114,696———114,696
Net income—————2,753,1382,753,138
Other comprehensive loss————(197)—(197)
Cash dividends declared ($0.33 per common share)—————(412,218)(412,218)
Balance at September 27, 20261,249,145$1,249$9,363,408$(32,620,072)$(127,285)$37,291,174$13,908,474
Three Months Ended
September 28, 2025
Common Stock SharesCommon StockAdditional Paid-in CapitalTreasury StockAccumulated Other Comprehensive LossRetained EarningsTotal
Balance at June 29, 20251,268,740$1,268$8,697,290$(27,763,430)$(62,423)$28,988,914$9,861,619
Issuance of common stock178——————
Purchase of treasury stock(9,742)(10)—(996,083)——(996,093)
Equity-based compensation expense——97,241———97,241
Net income—————1,568,6601,568,660
Other comprehensive loss————(11,168)—(11,168)
Cash dividends declared ($0.26 per common share)—————(327,507)(327,507)
Balance at September 28, 20251,259,176$1,258$8,794,531$(28,759,513)$(73,591)$30,230,067$10,192,752

See Notes to Condensed Consolidated Financial Statements

Lam Research Corporation 2027 Q1 10-Q 8

LAM RESEARCH CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 27, 2026

(Unaudited)

NOTE 1 — BASIS OF PRESENTATION

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the periods presented have been included. The accompanying unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements of Lam Research Corporation (“Lam Research” or the “Company”) for the fiscal year ended June 28, 2026, which are included in the Company’s Annual Report on Form 10-K as of and for the year ended June 28, 2026 (the “2026 Form 10-K”).

The Condensed Consolidated Financial Statements include the accounts of Lam Research and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company’s reporting period is a 52/53-week fiscal year. The Company’s current fiscal year will end June 27, 2027 and includes 52 weeks. The quarters ended September 27, 2026 and September 28, 2025 included 13 weeks.

NOTE 2 — RECENT ACCOUNTING PRONOUNCEMENTS

Recently Adopted or Effective

The Company has not adopted any new accounting standards during the three months ended September 27, 2026 that have a material impact on the Company’s Condensed Consolidated Financial Statements.

NOTE 3 — REVENUE

Disaggregation of Revenue

The Company operates in seven geographic regions: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. For geographical reporting, revenue is attributed to the geographic location in which the customers’ facilities are located. The Company serves three primary markets: memory, foundry, and logic/integrated device manufacturing.

The following table presents the Company’s revenues disaggregated between systems and customer support-related revenue:

Three Months Ended
September 27, 2026September 28, 2025
(in thousands)
Systems revenue$5,732,907$3,547,565
Customer support-related revenue and other2,486,5111,776,608
$8,219,418$5,324,173

Systems revenue includes sales of new leading-edge equipment in deposition, etch, clean and other wafer fabrication markets.

Customer support-related revenue includes sales of customer services, spares, upgrades, and non-leading-edge equipment from the Company’s Reliant® product line.

Lam Research Corporation 2027 Q1 10-Q 9

The following table presents the Company’s revenues disaggregated by geographic region:

Three Months Ended
September 27, 2026September 28, 2025
Revenue:(in thousands)
China$2,885,608$2,282,573
Korea1,634,115776,301
Taiwan1,482,0871,027,214
Japan721,509529,297
United States663,102304,716
Southeast Asia531,694302,254
Europe301,303101,818
$8,219,418$5,324,173

The following table presents the percentages of leading- and non-leading-edge equipment and upgrade revenue to each of the primary markets the Company serves:

Three Months Ended
September 27, 2026September 28, 2025
Foundry46%60%
Memory46%34%
Logic/integrated device manufacturing8%6%

Deferred Revenue

Revenue of $901.2 million included in deferred profit at June 28, 2026 was recognized during the three months ended September 27, 2026, representing 37% of the $2.43 billion of deferred revenue as of June 28, 2026.

The following table summarizes the transaction price for contracts that have not yet been recognized as revenue as of September 27, 2026 and when the Company expects to recognize the amounts as revenue:

Less than 1 Year1-3 YearsMore than 3 YearsTotal
(in thousands)
Deferred revenue$2,026,932$539,916(1)$94,383(1)$2,661,231

(1)This amount is reported in Deferred profit on the Company's Condensed Consolidated Balance Sheets as the customers can demand the performance to be satisfied at any time.

NOTE 4 — EQUITY-BASED COMPENSATION PLANS

The Lam Research Corporation 2015 Stock Incentive Plan, as amended, and the Lam Research Corporation 2025 Stock Incentive Plan provide for the grant of non-qualified equity-based awards of the Company’s Common Stock to eligible employees and non-employee directors, including stock options, restricted stock units (“RSUs”), and market-based performance RSUs (“market-based PRSUs”). An option is a right to purchase Common Stock at a set price. An RSU award is an agreement to issue a set number of shares of Common Stock at the time of vesting. The Company’s market-based PRSUs contain both a market condition and a service condition. The Company’s option, RSU, and market-based PRSU awards typically vest over a period of three years. The Company also has an employee stock purchase plan that allows eligible employees to purchase its Common Stock at a discount through payroll deductions.

The Company recognized the following equity-based compensation expense (including expense related to the employee stock purchase plan) in the Condensed Consolidated Statements of Operations:

Three Months Ended
September 27, 2026September 28, 2025
(in thousands)
Equity-based compensation expense$114,696$97,241

Lam Research Corporation 2027 Q1 10-Q 10

NOTE 5 — OTHER INCOME (EXPENSE), NET

The significant components of other income (expense), net, are as follows:

Three Months Ended
September 27, 2026September 28, 2025
(in thousands)
Interest income$49,849$63,930
Interest expense(36,762)(42,472)
Gains on deferred compensation plan-related assets, net12,87023,088
Foreign exchange gains (losses), net3,889(5,534)
Other, net(1,353)(8,938)
$28,493$30,074

NOTE 6 — INCOME TAX EXPENSE

The Company’s provision for income taxes and effective tax rate are as follows:

Three Months Ended
September 27, 2026September 28, 2025
(in thousands, except percentages)
Income tax expense$559,082$290,502
Effective tax rate16.9%15.6%

The difference between the U.S. federal statutory tax rate of 21% and the Company’s effective tax rate for the three months ended September 27, 2026, and September 28, 2025, was primarily due to income in lower tax jurisdictions.

NOTE 7 — NET INCOME PER SHARE

Basic net income per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed using the treasury stock method, for dilutive stock options, and restricted stock units. The following table reconciles the inputs to the basic and diluted computations for net income per share.

Three Months Ended
September 27, 2026September 28, 2025
(in thousands, except per share data)
Numerator:
Net income$2,753,138$1,568,660
Denominator:
Basic average shares outstanding1,250,8831,264,446
Effect of potential dilutive securities:
Employee stock plans4,8854,867
Diluted average shares outstanding1,255,7681,269,313
Net income per share - basic$2.20$1.24
Net income per share - diluted$2.19$1.24

For purposes of computing diluted net income per share, weighted-average shares of common stock do not include potentially dilutive securities that are anti-dilutive under the treasury stock method. These anti-dilutive securities, including options and RSUs, were not material for the three months ended September 27, 2026 and September 28, 2025.

Lam Research Corporation 2027 Q1 10-Q 11

NOTE 8 — FINANCIAL INSTRUMENTS

There have been no material changes to the Company’s investment strategies and investment and fair value policies to those disclosed in Note 9, “Financial Instruments,” to the Consolidated Financial Statements in Part II, Item 8 of its 2026 Form 10-K. As of September 27, 2026 and June 28, 2026, the fair values of mutual funds and equity investments were not material. The Company had no debt security investments as of September 27, 2026 and June 28, 2026. The financial statement impacts to the Condensed Consolidated Statement of Operations from debt and equity investments were not material as of and for the three months ended September 27, 2026 and September 28, 2025.

The financial instruments reported within Cash and Cash Equivalents in the Company’s Condensed Consolidated Balance Sheets as of September 27, 2026, and June 28, 2026 consisted of the following:

September 27, 2026June 28, 2026
(in thousands)
Money market funds (fair value measured on a recurring basis, level 1)$3,270,420$2,015,275
Cash2,037,5932,071,271
Time deposits2,129,3711,492,625
$7,437,384$5,579,171

Derivative Instruments and Hedging

There have been no material changes to the Company’s hedging strategies and policies to those disclosed in Note 9, “Financial Instruments,” to the Consolidated Financial Statements in Part II, Item 8 of its 2026 Form 10-K. As of September 27, 2026 and June 28, 2026, the fair value of outstanding cash flow and balance sheet hedges were not material. The financial statement impacts to the Condensed Consolidated Statement of Operations from derivative instruments and hedging activities were not material as of and for the three months ended September 27, 2026 and September 28, 2025.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk and the Company’s mitigation strategies are materially the same as those disclosed in Note 9, “Financial Instruments,” to the Consolidated Financial Statements in Part II, Item 8 of its 2026 Form 10-K.

NOTE 9 — INVENTORIES

Inventories are stated at the lower of cost or net realizable value using standard costs that approximate actual costs on a first-in, first-out basis. Inventories consist of the following:

September 27, 2026June 28, 2026
(in thousands)
Raw materials$2,837,122$2,551,150
Work-in-process432,082449,669
Finished goods1,281,3401,275,292
$4,550,544$4,276,111

Lam Research Corporation 2027 Q1 10-Q 12

NOTE 10 — PROPERTY AND EQUIPMENT, NET

Property and equipment, net is presented in the table below:

September 27, 2026June 28, 2026
(in thousands)
Manufacturing and engineering equipment$2,648,558$2,559,970
Buildings and improvements2,418,6282,289,208
Computer and computer-related equipment201,551192,354
Land268,471264,507
Office equipment, furniture and fixtures123,176114,797
5,660,3845,420,836
Less: accumulated depreciation and amortization$(2,583,166)$(2,484,833)
$3,077,218$2,936,003

The Company has excluded immaterial right-of-use assets, under finance leases, recorded within property and equipment, net from the table above.

NOTE 11 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consist of the following:

September 27, 2026June 28, 2026
(in thousands)
Accrued compensation$867,435$695,498
Warranty reserves320,689270,044
Income and other taxes payable800,781263,205
Dividends payable412,218325,402
Other886,340797,392
$3,287,463$2,351,541

NOTE 12 — COMMITMENTS AND CONTINGENCIES

Guarantees

The Company has issued certain indemnifications to its lessors for taxes and general liability under some of its agreements. The Company has entered into insurance contracts that are intended to limit its exposure to such indemnifications. As of September 27, 2026, the Company had not recorded any liability on its Condensed Consolidated Financial Statements in connection with these indemnifications, as it does not believe, based on historical experience and information currently available, that it is probable that any material amounts will be paid under these guarantees.

Generally, the Company indemnifies, under pre-determined conditions and limitations, its customers for infringement of third-party intellectual property rights by the Company’s products or services. The Company seeks to limit its liability for such indemnity to an amount not to exceed the sales price of the products or services subject to its indemnification obligations. The Company does not believe, based on historical experience and information currently available, that it is probable that any material amounts will be paid under these guarantees.

The Company provides guarantees and standby letters of credit to certain parties as required for certain transactions initiated during the ordinary course of business. As of September 27, 2026, the maximum potential amount of future payments that the Company could be required to make under these arrangements and letters of credit was $290.3 million. The Company does not believe, based on historical experience and information currently available, that it is probable that any material amounts will be required to be paid.

In addition, the Company has entered into indemnification agreements with its directors, officers, and certain other employees, consistent with its Bylaws and Certificate of Incorporation; and under local law, the Company may be required to provide indemnification to its employees for actions within the scope of their employment. Although the Company maintains insurance contracts that cover some of the potential liability associated with these indemnification agreements, there is no guarantee that all such liabilities will be covered. The Company does not believe, based on historical experience and information currently available,

Lam Research Corporation 2027 Q1 10-Q 13

that it is probable that any material amounts will be required to be paid under such indemnification agreements or statutory obligations.

Warranties

The Company provides standard warranties on its systems. The liability amount is based on actual historical warranty spending activity by type of system, customer, and geographic region, modified for any known differences such as the impact of system reliability improvements. As of September 27, 2026, warranty reserves totaling $21.5 million were reported in Other long-term liabilities, and the remainder were included in Accrued expenses and other current liabilities in the Company’s Condensed Consolidated Balance Sheets.

Changes in the Company’s product warranty reserves were as follows:

Three Months Ended
September 27, 2026September 28, 2025
(in thousands)
Balance at beginning of period$289,713$265,466
Warranties issued during the period124,60065,584
Settlements made during the period(57,078)(64,525)
Changes in liability for pre-existing warranties(15,002)(8,659)
Balance at end of period$342,233$257,866

Legal Proceedings

While the Company is not currently a party to any legal proceedings that it believes material, the Company is either a defendant or plaintiff in various actions that have arisen from time to time in the normal course of business, including intellectual property claims. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. Based on current information, the Company does not believe that a material loss from known matters is probable and therefore has not recorded an accrual of any material amount for litigation or other contingencies related to existing legal proceedings.

NOTE 13 — STOCK REPURCHASE PROGRAM

In May 2024, the Board of Directors authorized the Company to repurchase up to an additional $10.00 billion of Common Stock; this authorization supplements the remaining balance from any prior authorizations. These repurchases can be conducted on the open market or as private purchases and may include the use of derivative contracts with large financial institutions, in all cases subject to compliance with applicable law. This repurchase program has no termination date and may be suspended or discontinued at any time.

Repurchases under the repurchase program were as follows during the periods indicated.

PeriodTotal Number of Shares RepurchasedTotal Cost of Repurchase (1)Average Price Paid per Share (1,2)Amount Available Under Repurchase Program
(in thousands, except per share data)
Available balance as of June 28, 2026$4,042,724
Quarter ended September 27, 20262,344(3)$1,010,711$329.17$3,032,013

(1) The Company’s net share repurchases are subject to a 1% excise tax under the Inflation Reduction Act. Excise tax incurred reduces the amount available under the repurchase program, as applicable, and is included in the cost of shares repurchased in the Condensed Consolidated Statement of Stockholders’ Equity and the calculation of the average price paid per share.

(2) Average price paid per share excludes the effect of accelerated share repurchase activities. See additional disclosure below regarding the Company’s accelerated share repurchase activity during the fiscal year.

(3) Includes shares received at initial or final settlement of accelerated share repurchase agreements. See additional disclosure below regarding the Company’s accelerated share repurchase activity during the fiscal year.

Accelerated Share Repurchase Agreements

During the three months ended September 27, 2026, the Company entered into accelerated share repurchase agreements (the “September 2026 ASRs”) with two financial institutions to repurchase a total of $1.00 billion of Common Stock. The Company took an initial delivery of approximately 2.3 million shares, which represented 75% of the prepayment amount divided by the Company’s

Lam Research Corporation 2027 Q1 10-Q 14

closing stock price on the date of execution. The total number of shares to be received under the September 2026 ASRs will be based upon the average daily volume weighted average price of the Company’s Common Stock during the repurchase period, less an agreed upon discount. The September 2026 ASRs are expected to fully settle in the quarter ended December 27, 2026.

The Company recorded each of the September 2026 ASRs as equity transactions; as such, at the time of receipt, shares were included in treasury stock at fair market value as of the corresponding trade date. The Company reflects shares received as a repurchase of common stock in the weighted average shares of common stock outstanding calculation for basic and diluted earnings per share.

NOTE 14 — SEGMENT REPORTING

The Company operates in one reportable business segment: manufacturing and servicing of wafer processing semiconductor manufacturing equipment. The Company’s material operating segments qualify for aggregation due to their customer base and similarities in economic characteristics, nature of products and services, and processes for procurement, manufacturing, and distribution.

Segment information is prepared and managed on the same basis as described in Note 19, “Segment, Geographic Information, and Major Customers,” to the Consolidated Financial Statements in Part II, Item 8 of the Company’s 2026 Form 10-K.

The Company's centralized manufacturing and support organizations, including global operations and certain administrative functions, provide support to its operating segments. Costs incurred by these organizations, as well as depreciation and amortization and equity-based compensation expense are allocated to cost of goods sold as overhead. Consequently, depreciation and amortization and equity-based compensation expense are not independently identifiable components within the segment’s results and, therefore, are not provided.

With the exception of goodwill, the Company does not identify assets by operating segment. Consequently, the chief operating decision maker does not regularly review or receive discrete asset information by operating segment.

The table below reconciles the Company's reportable segment to income before income taxes:

Three Months Ended
September 27, 2026September 28, 2025
(In thousands)
Revenue$8,219,418$5,324,173
Installation and warranty expense234,051141,475
Other cost of goods sold (COGS) (1)3,532,8852,410,985
Segment COGS3,766,9362,552,460
Segment gross margin4,452,4822,771,713
Reconciliation to consolidated gross margin
All other COGS153,62986,834
Gross margin4,298,8532,684,879
Research and development666,398576,446
Selling, general, and administrative348,728279,345
Other income (expense), net28,49330,074
Income before income taxes$3,312,220$1,859,162

(1)Other COGS is primarily comprised of the capitalized cost of inventory sold, including both direct and indirect costs, but excludes installation and warranty expense and those items not allocated to the segment.

Lam Research Corporation 2027 Q1 10-Q 15

Previous: Cover and table of contents · Next: Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations